

Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

Listing of Claims

Claims 1-57 (canceled)

58. (currently amended) A method for treatment of a patient having a ~~metastatic~~ tumor, said tumor comprising a population of tumor ~~metastatic~~ cells that express EphA2, said method comprising administering to the patient a therapeutically effective amount of an ephrin comprising the extracellular domain of ephrinA1 ~~a compound~~ that increases the phosphotyrosine content of EphA2, wherein said administration reduces tumor volume ~~metastasis~~.

59. (currently amended) The method of claim 58 wherein the tumor ~~metastatic~~ cells overexpress EphA2 as compared to normal cells.

60. (currently amended) The method of claim 58 wherein said administration inhibits proliferation of the tumor ~~metastatic~~ cells.

61. (previously presented) The method of claim 58 wherein said administration reduces invasiveness of the tumor ~~metastatic~~ cells compared to untreated tumor ~~metastatic~~ cells.

62. (currently amended) A method for treatment of a patient having a ~~metastatic~~ tumor, said tumor comprising a population of tumor ~~metastatic~~ cells that express EphA2, said method comprising administering to the patient a therapeutically effective amount of an ephrin comprising the extracellular domain of ephrinA1 ~~a compound~~ that increases the phosphotyrosine

content of EphA2, wherein said administration impedes proliferation of said tumor ~~metastatic~~ cells.

63. (currently amended) The method of claim 62 wherein the tumor ~~metastatic~~ cells overexpress EphA2 as compared to normal cells.

64. (currently amended) A method for treatment of a patient having a ~~metastatic~~ tumor, said tumor comprising a population of tumor ~~metastatic~~ cells that express EphA2, said method comprising administering to the patient a therapeutically effective amount of an ephrin comprising the extracellular domain of ephrinA1 ~~a compound~~ that increases the phosphotyrosine content of EphA2 in said tumor ~~metastatic~~ cells as compared to untreated tumor ~~metastatic~~ cells.

65. (currently amended) The method of claim [[58]] 64 wherein the tumor ~~metastatic~~ cells overexpress EphA2 as compared to normal cells.

66. (currently amended) A method for reducing the invasiveness of a ~~metastatic~~ cancer cell that expresses EphA2, the method comprising contacting the cancer ~~metastatic~~ cell with an ephrin comprising the extracellular domain of ephrinA1 ~~a compound~~ that increases the phosphotyrosine content of EphA2, thereby reducing the invasiveness of the cancer ~~metastatic~~ cell compared to an untreated cancer ~~metastatic~~ cell.

67. (currently amended) The method of claim 66 wherein the cancer ~~metastatic~~ cell overexpresses EphA2 as compared to a normal cell.

68. (currently amended) The method of claim 66 wherein the cancer ~~metastatic~~ cell is present in a mammalian patient.

69. (currently amended) A method for reducing the proliferative behavior of a ~~metastatic~~ cancer cell that expresses EphA2, the method comprising contacting the ~~metastatic~~ cancer cell with an ephrin comprising the extracellular domain of ephrinA1 ~~a compound~~ that increases the phosphotyrosine content of EphA2, thereby reducing the proliferative behavior of said cancer ~~metastatic~~ cell compared to an untreated cancer ~~metastatic~~ cell.

70. (currently amended) The method of claim 69 wherein the cancer ~~metastatic~~ cell overexpresses EphA2 as compared to a normal cell.

71. (currently amended) The method of claim 69 wherein the cancer ~~metastatic~~ cell is present in a mammalian patient.

72. (currently amended) A method for treatment of a patient having a ~~metastatic~~ tumor, said tumor comprising a population of tumor ~~metastatic~~ cells that express EphA2, said method comprising administering to the patient a therapeutically effective amount of an anti-EphA2 antibody that increases the phosphotyrosine content of EphA2, wherein said administration reduces tumor volume ~~metastasis~~.

73. (currently amended) The method of claim 72 wherein the tumor ~~metastatic~~ cells overexpress EphA2 as compared to normal cells.

74. (currently amended) The method of claim 72 wherein said administration inhibits proliferation of the tumor ~~metastatic~~ cells.

75. (currently amended) The method of claim 72 wherein said administration reduces invasiveness of the tumor ~~metastatic~~ cells compared to untreated tumor ~~metastatic~~ cells.

76. (previously presented) The method of claim 72 wherein the anti-EphA2 antibody is a monoclonal antibody.

77. (previously presented) The method of claim 76 wherein the monoclonal antibody is humanized.

78. (previously presented) The method of claim 76 wherein the monoclonal antibody is conjugated to a cytotoxic agent.

79. (currently amended) A method for treatment of a patient having a ~~metastatic~~ tumor, said tumor comprising a population of tumor ~~metastatic~~ cells that express EphA2, said method comprising administering to the patient a therapeutically effective amount of an anti-EphA2 antibody that increases the phosphotyrosine content of EphA2, wherein said administration impedes proliferation of said tumor ~~metastatic~~ cells.

80. (currently amended) The method of claim 79 wherein the ~~metastatic~~ cells overexpress EphA2 as compared to normal cells.

81. (previously presented) The method of claim 79 wherein the anti-EphA2 antibody is a monoclonal antibody.

82. (previously presented) The method of claim 81 wherein the monoclonal antibody is humanized.

83. (previously presented) The method of claim 81 wherein the monoclonal antibody is conjugated to a cytotoxic agent.

84. (currently amended) A method for treatment of a patient having a ~~metastatic~~ tumor, said tumor comprising a population of tumor ~~metastatic~~ cells that express EphA2, said method comprising administering to the patient a therapeutically effective amount of an anti-EphA2 antibody that increases the phosphotyrosine content of EphA2 in said tumor ~~metastatic~~ cells as compared to untreated tumor ~~metastatic~~ cells.

85. (currently amended) The method of claim 84 wherein the tumor ~~metastatic~~ cells overexpress EphA2 as compared to normal cells.

86. (previously presented) The method of claim 84 wherein the anti-EphA2 antibody is a monoclonal antibody.

87. (previously presented) The method of claim 86 wherein the monoclonal antibody is humanized.

88. (previously presented) The method of claim 86 wherein the monoclonal antibody is conjugated to a cytotoxic agent.

89. (currently amended)) A method for reducing the invasiveness of a ~~metastatic~~ cancer cell that expresses EphA2, the method comprising contacting the cancer ~~metastatic~~ cell with an anti-EphA2 antibody that increases the phosphotyrosine content of EphA2, thereby reducing the invasiveness of the cancer ~~metastatic~~ cell compared to an untreated cancer ~~metastatic~~ cell.

90. (currently amended) The method of claim 89 wherein the cancer ~~metastatic~~ cell overexpresses EphA2 as compared to a normal cell.

91. (currently amended) The method of claim 89 wherein the cancer ~~metastatic~~ cell is present in a mammalian patient.

92. (previously presented) The method of claim 89 wherein the anti-EphA2 antibody is a monoclonal antibody.

93. (previously presented) The method of claim 92 wherein the monoclonal antibody is humanized.

94. (previously presented) The method of claim 92 wherein the monoclonal antibody is conjugated to a cytotoxic agent.

95. (currently amended) A method for reducing the proliferative behavior of a ~~metastatic~~ cancer cell that expresses EphA2, the method comprising contacting the ~~metastatic~~ cancer cell with an anti-EphA2 antibody that increases the phosphotyrosine content of EphA2, thereby reducing the proliferative behavior of said cancer ~~metastatic~~ cell compared to an untreated ~~metastatic~~ cell.

96. (currently amended) The method of claim 95 wherein the cancer ~~metastatic~~ cell overexpresses EphA2 as compared to a normal cell.

97. (currently amended) The method of claim 95 wherein the cancer ~~metastatic~~ cell is present in a mammalian patient.

98. (previously presented) The method of claim 97 wherein the anti-EphA2 antibody is a monoclonal antibody.

99. (previously presented) The method of claim 97 wherein the monoclonal antibody is humanized.

100. (previously presented) The method of claim 97 wherein the monoclonal antibody is conjugated to a cytotoxic agent.

101. (currently amended) The method of any one of claims 58, 62, 64, ~~[[66 or 69]]~~ 72, 79 or 84 wherein the population of tumor cells comprises cells selected from the group consisting of breast cancer cells, prostate cancer cells, lung cancer cells and colon cancer cells.

102. (currently amended) The method of any one of claims 66, 69, ~~[[72, 79, 84,]]~~ 89 or 95 wherein the ~~metastatic~~ cancer cell is a cell selected from the group consisting of a breast cancer cell, prostate cancer cell, lung cancer cell and colon cancer cell.

103. (new) The method of any of claims 58, 62, 64, 66 or 69 wherein the ephrin comprises ephrinA1-Fc.